Symbols / COLL $33.06 -0.63% Collegium Pharmaceutical, Inc.
COLL Chart
About
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Fundamentals
Scroll to Statements| Market Cap | 1.07B | Enterprise Value | 1.61B | Income | 62.87M | Sales | 780.57M | Book/sh | 9.51 | Cash/sh | 12.18 |
| Dividend Yield | — | Payout | 0.00% | Employees | 423 | IPO | — | P/E | 19.11 | Forward P/E | 4.98 |
| PEG | — | P/S | 1.37 | P/B | 3.47 | P/C | — | EV/EBITDA | 3.83 | EV/Sales | 2.06 |
| Quick Ratio | 1.36 | Current Ratio | 1.57 | Debt/Eq | 310.41 | LT Debt/Eq | — | EPS (ttm) | 1.73 | EPS next Y | 6.64 |
| EPS Growth | 31.50% | Revenue Growth | 12.90% | Earnings | 2026-05-07 | ROA | 7.27% | ROE | 23.70% | ROIC | — |
| Gross Margin | 88.86% | Oper. Margin | 30.04% | Profit Margin | 8.05% | Shs Outstand | 32.41M | Shs Float | 31.30M | Short Float | 20.40% |
| Short Ratio | 8.44 | Short Interest | — | 52W High | 50.79 | 52W Low | 25.86 | Beta | 0.77 | Avg Volume | 507.22K |
| Volume | 281.34K | Target Price | $54.17 | Recom | Buy | Prev Close | $33.27 | Price | $33.06 | Change | -0.63% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2026-03-19 | reit | Needham | Buy → Buy | $56 |
| 2026-02-26 | main | Needham | Buy → Buy | $54 |
| 2026-01-09 | main | Barclays | Overweight → Overweight | $56 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2026-01-08 | main | Needham | Buy → Buy | $56 |
| 2025-12-09 | init | Barclays | — → Overweight | $58 |
| 2025-11-07 | main | Truist Securities | Buy → Buy | $48 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $46 |
| 2025-10-28 | reit | Needham | Buy → Buy | $46 |
| 2025-05-09 | reit | Piper Sandler | Neutral → Neutral | $37 |
| 2025-04-09 | reit | Needham | Buy → Buy | $46 |
| 2025-03-24 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-02-04 | main | Piper Sandler | Neutral → Neutral | $36 |
| 2025-01-10 | up | Needham | Hold → Buy | $46 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-10-11 | reit | Piper Sandler | Neutral → Neutral | $37 |
| 2024-09-05 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-08-09 | reit | Piper Sandler | Neutral → Neutral | $37 |
| 2024-08-09 | main | Truist Securities | Buy → Buy | $42 |
- Collegium Pharmaceutical Inc (COLL) Stock Down 5.4% -- Now Under - GuruFocus Fri, 17 Apr 2026 07
- Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today - Yahoo Finance Fri, 27 Feb 2026 08
- COLL SEC Filings - Collegium Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan Fri, 10 Apr 2026 01
- Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a 64% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews Fri, 17 Apr 2026 09
- Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Down 4.6% - Here's What Happened - MarketBeat hu, 16 Apr 2026 17
- COLLEGIUM PHARMACEUTICAL ($COLL) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Feb 2026 08
- Is Collegium Pharmaceutical (COLL) one of the best small-cap drug manufacturers? - MSN Sun, 19 Apr 2026 17
- Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 - The Motley Fool Wed, 14 Jan 2026 08
- Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case - ChartMill Sat, 28 Mar 2026 07
- Assessing Collegium Pharmaceutical (COLL) Valuation After Mixed Recent Share Price Performance - simplywall.st Fri, 10 Apr 2026 07
- Collegium to webcast Needham fireside chat, post 90-day replay - Stock Titan Wed, 08 Apr 2026 07
- A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Swings - Yahoo Finance Sun, 18 Jan 2026 08
- Collegium (COLL) EVP has 8,840 shares withheld for RSU tax payment - Stock Titan Fri, 03 Apr 2026 07
- Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results - Yahoo Finance ue, 10 Mar 2026 07
- Why Collegium Pharmaceutical (COLL) Is Down 7.4% After Reaffirming 2026 Revenue Guidance Despite Earnings Miss - Yahoo Finance Fri, 27 Feb 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
780.57
+23.62%
|
631.45
+11.41%
|
566.77
+22.17%
|
463.93
|
| Operating Revenue |
|
780.57
+23.62%
|
631.45
+11.41%
|
566.77
+22.17%
|
463.93
|
| Cost Of Revenue |
|
317.31
+24.87%
|
254.10
+5.61%
|
240.60
-5.44%
|
254.44
|
| Reconciled Cost Of Revenue |
|
317.31
+24.87%
|
254.10
+5.61%
|
240.60
-5.44%
|
254.44
|
| Gross Profit |
|
463.26
+22.77%
|
377.34
+15.69%
|
326.17
+55.70%
|
209.49
|
| Operating Expense |
|
284.80
+35.39%
|
210.36
+32.13%
|
159.21
-9.63%
|
176.17
|
| Research And Development |
|
—
|
0.00
|
0.00
-100.00%
|
3.98
|
| Selling General And Administration |
|
284.80
+35.39%
|
210.36
+32.13%
|
159.21
-7.54%
|
172.19
|
| Total Expenses |
|
602.11
+29.63%
|
464.47
+16.17%
|
399.81
-7.15%
|
430.61
|
| Operating Income |
|
178.45
+6.87%
|
166.98
+0.01%
|
166.96
+401.10%
|
33.32
|
| Total Operating Income As Reported |
|
179.64
+5.73%
|
169.90
+1.76%
|
166.96
+401.10%
|
33.32
|
| EBITDA |
|
401.00
+17.36%
|
341.70
+10.82%
|
308.33
+77.91%
|
173.31
|
| Normalized EBITDA |
|
415.82
+18.77%
|
350.12
+5.51%
|
331.83
+91.47%
|
173.31
|
| Reconciled Depreciation |
|
226.07
+33.65%
|
169.16
+13.34%
|
149.26
+7.43%
|
138.94
|
| EBIT |
|
174.93
+1.38%
|
172.54
+8.47%
|
159.07
+362.88%
|
34.37
|
| Total Unusual Items |
|
-14.81
-76.02%
|
-8.41
+64.20%
|
-23.50
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-14.81
-76.02%
|
-8.41
+64.20%
|
-23.50
|
0.00
|
| Special Income Charges |
|
-14.81
-76.02%
|
-8.41
+64.20%
|
-23.50
|
0.00
|
| Other Special Charges |
|
15.99
+41.18%
|
11.33
-51.80%
|
23.50
|
—
|
| Restructuring And Mergern Acquisition |
|
-1.18
+59.44%
|
-2.91
|
0.00
|
0.00
|
| Net Income |
|
62.87
-9.13%
|
69.19
+43.68%
|
48.16
+292.60%
|
-25.00
|
| Pretax Income |
|
92.62
-6.04%
|
98.57
+30.15%
|
75.73
+362.53%
|
-28.85
|
| Net Non Operating Interest Income Expense |
|
-71.02
-18.38%
|
-60.00
+11.41%
|
-67.72
-8.94%
|
-62.17
|
| Interest Expense Non Operating |
|
82.31
+11.27%
|
73.97
-11.24%
|
83.34
+31.84%
|
63.21
|
| Net Interest Income |
|
-71.02
-18.38%
|
-60.00
+11.41%
|
-67.72
-8.94%
|
-62.17
|
| Interest Expense |
|
82.31
+11.27%
|
73.97
-11.24%
|
83.34
+31.84%
|
63.21
|
| Interest Income Non Operating |
|
11.29
-19.23%
|
13.98
-10.50%
|
15.62
+1391.40%
|
1.05
|
| Interest Income |
|
11.29
-19.23%
|
13.98
-10.50%
|
15.62
+1391.40%
|
1.05
|
| Other Income Expense |
|
-14.81
-76.02%
|
-8.41
+64.20%
|
-23.50
|
—
|
| Tax Provision |
|
29.75
+1.26%
|
29.38
+6.53%
|
27.58
+817.24%
|
-3.85
|
| Tax Rate For Calcs |
|
0.00
+7.72%
|
0.00
-18.13%
|
0.00
+173.68%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-4.75
-89.60%
|
-2.51
+70.69%
|
-8.56
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
62.87
-9.13%
|
69.19
+43.68%
|
48.16
+292.60%
|
-25.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
62.87
-9.13%
|
69.19
+43.68%
|
48.16
+292.60%
|
-25.00
|
| Net Income From Continuing And Discontinued Operation |
|
62.87
-9.13%
|
69.19
+43.68%
|
48.16
+292.60%
|
-25.00
|
| Net Income Continuous Operations |
|
62.87
-9.13%
|
69.19
+43.68%
|
48.16
+292.60%
|
-25.00
|
| Normalized Income |
|
72.93
-2.89%
|
75.10
+19.01%
|
63.10
+352.39%
|
-25.00
|
| Net Income Common Stockholders |
|
62.87
-9.13%
|
69.19
+43.68%
|
48.16
+292.60%
|
-25.00
|
| Diluted EPS |
|
1.73
-6.99%
|
1.86
+44.19%
|
1.29
+274.32%
|
-0.74
|
| Basic EPS |
|
1.98
-7.48%
|
2.14
+49.65%
|
1.43
+293.24%
|
-0.74
|
| Basic Average Shares |
|
31.71
-1.76%
|
32.27
-4.35%
|
33.74
-0.26%
|
33.83
|
| Diluted Average Shares |
|
39.70
-1.79%
|
40.42
-3.26%
|
41.79
+23.53%
|
33.83
|
| Diluted NI Availto Com Stockholders |
|
68.88
-8.23%
|
75.05
+38.87%
|
54.04
+316.16%
|
-25.00
|
| Average Dilution Earnings |
|
6.01
+2.46%
|
5.86
-0.44%
|
5.89
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,656.83
-0.41%
|
1,663.59
+45.51%
|
1,143.31
-2.63%
|
1,174.13
|
| Current Assets |
|
691.41
+43.37%
|
482.26
-10.29%
|
537.60
+28.00%
|
419.99
|
| Cash Cash Equivalents And Short Term Investments |
|
386.68
+137.57%
|
162.76
-47.59%
|
310.55
+78.80%
|
173.69
|
| Cash And Cash Equivalents |
|
231.25
+227.71%
|
70.56
-70.47%
|
238.95
+37.57%
|
173.69
|
| Other Short Term Investments |
|
155.43
+68.58%
|
92.20
+28.77%
|
71.60
|
0.00
|
| Receivables |
|
211.33
-7.53%
|
228.54
+27.30%
|
179.53
-1.96%
|
183.12
|
| Accounts Receivable |
|
211.33
-7.53%
|
228.54
+27.30%
|
179.53
-1.96%
|
183.12
|
| Inventory |
|
40.91
+15.05%
|
35.56
+9.98%
|
32.33
-30.47%
|
46.50
|
| Raw Materials |
|
—
|
—
|
10.38
+85.43%
|
5.60
|
| Work In Process |
|
—
|
—
|
6.74
-72.68%
|
24.67
|
| Finished Goods |
|
—
|
—
|
15.21
-6.29%
|
16.23
|
| Prepaid Assets |
|
29.40
+6.33%
|
27.65
+83.10%
|
15.10
-9.16%
|
16.62
|
| Restricted Cash |
|
19.85
-20.60%
|
25.00
|
0.00
|
—
|
| Other Current Assets |
|
3.24
+18.13%
|
2.74
+2848.39%
|
0.09
+63.16%
|
0.06
|
| Total Non Current Assets |
|
965.42
-18.28%
|
1,181.33
+95.03%
|
605.71
-19.68%
|
754.14
|
| Net PPE |
|
16.20
-19.61%
|
20.15
-8.45%
|
22.01
-16.56%
|
26.38
|
| Gross PPE |
|
32.74
-2.80%
|
33.69
+6.30%
|
31.69
-3.10%
|
32.70
|
| Accumulated Depreciation |
|
-16.54
-22.23%
|
-13.53
-39.84%
|
-9.68
-53.06%
|
-6.32
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
3.99
-13.07%
|
4.59
+30.39%
|
3.52
-2.84%
|
3.62
|
| Construction In Progress |
|
1.75
+117.71%
|
0.80
|
0.00
|
0.00
|
| Other Properties |
|
25.77
-4.76%
|
27.06
-0.17%
|
27.11
-3.90%
|
28.21
|
| Leases |
|
1.23
+0.00%
|
1.23
+16.02%
|
1.06
+21.40%
|
0.87
|
| Goodwill And Other Intangible Assets |
|
815.43
-22.61%
|
1,053.73
+89.67%
|
555.57
-20.77%
|
701.16
|
| Goodwill |
|
145.93
-10.11%
|
162.33
+21.27%
|
133.86
+0.12%
|
133.69
|
| Other Intangible Assets |
|
669.51
-24.89%
|
891.40
+111.38%
|
421.71
-25.69%
|
567.47
|
| Non Current Deferred Assets |
|
112.54
+14.80%
|
98.03
+273.33%
|
26.26
+9.64%
|
23.95
|
| Non Current Deferred Taxes Assets |
|
112.54
+14.80%
|
98.03
+273.33%
|
26.26
+9.64%
|
23.95
|
| Other Non Current Assets |
|
21.25
+125.69%
|
9.41
+402.94%
|
1.87
-29.28%
|
2.65
|
| Total Liabilities Net Minority Interest |
|
1,355.16
-5.55%
|
1,434.75
+51.36%
|
947.88
-3.21%
|
979.29
|
| Current Liabilities |
|
440.03
-13.64%
|
509.51
+11.27%
|
457.92
+5.58%
|
433.73
|
| Payables And Accrued Expenses |
|
402.81
-7.62%
|
436.05
+60.18%
|
272.22
+1.34%
|
268.61
|
| Payables |
|
39.25
-18.35%
|
48.08
+203.48%
|
15.84
+101.90%
|
7.85
|
| Accounts Payable |
|
10.66
+170.95%
|
3.93
-54.74%
|
8.69
+148.77%
|
3.49
|
| Other Payable |
|
17.57
-39.34%
|
28.96
|
—
|
—
|
| Current Accrued Expenses |
|
363.55
-6.29%
|
387.97
+51.33%
|
256.38
-1.68%
|
260.76
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.71
-18.62%
|
4.56
+231.93%
|
1.38
-8.76%
|
1.51
|
| Total Tax Payable |
|
11.03
-27.37%
|
15.19
+112.41%
|
7.15
+64.27%
|
4.35
|
| Income Tax Payable |
|
3.30
-61.33%
|
8.53
+299.11%
|
2.14
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
30.41
-53.83%
|
65.85
-64.27%
|
184.32
+12.66%
|
163.61
|
| Current Debt |
|
29.00
-55.10%
|
64.58
-64.77%
|
183.33
+12.82%
|
162.50
|
| Other Current Borrowings |
|
29.00
-55.10%
|
64.58
-64.77%
|
183.33
+12.82%
|
162.50
|
| Current Capital Lease Obligation |
|
1.41
+10.70%
|
1.27
+28.64%
|
0.99
-11.15%
|
1.11
|
| Current Deferred Liabilities |
|
0.67
|
0.00
|
—
|
—
|
| Current Deferred Revenue |
|
0.67
|
0.00
|
—
|
—
|
| Other Current Liabilities |
|
2.44
-20.01%
|
3.04
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
915.13
-1.09%
|
925.24
+88.84%
|
489.96
-10.19%
|
545.56
|
| Long Term Debt And Capital Lease Obligation |
|
784.46
-1.13%
|
793.44
+61.94%
|
489.96
-10.19%
|
545.56
|
| Long Term Debt |
|
780.33
-0.96%
|
787.90
+62.84%
|
483.84
-10.14%
|
538.45
|
| Long Term Capital Lease Obligation |
|
4.13
-25.40%
|
5.54
-9.55%
|
6.12
-13.89%
|
7.11
|
| Non Current Deferred Liabilities |
|
130.67
+0.05%
|
130.61
|
0.00
|
—
|
| Non Current Deferred Revenue |
|
9.11
-8.89%
|
10.00
|
0.00
|
—
|
| Other Non Current Liabilities |
|
—
|
1.18
|
—
|
—
|
| Stockholders Equity |
|
301.68
+31.83%
|
228.84
+17.10%
|
195.43
+0.30%
|
194.84
|
| Common Stock Equity |
|
301.68
+31.83%
|
228.84
+17.10%
|
195.43
+0.30%
|
194.84
|
| Capital Stock |
|
0.04
+2.50%
|
0.04
+5.26%
|
0.04
+2.70%
|
0.04
|
| Common Stock |
|
0.04
+2.50%
|
0.04
+5.26%
|
0.04
+2.70%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
40.74
+2.75%
|
39.65
+3.81%
|
38.19
+2.99%
|
37.08
|
| Ordinary Shares Number |
|
31.71
+0.85%
|
31.44
-1.34%
|
31.87
-5.85%
|
33.85
|
| Treasury Shares Number |
|
9.03
+10.02%
|
8.21
+29.77%
|
6.32
+95.43%
|
3.24
|
| Additional Paid In Capital |
|
624.95
+5.88%
|
590.25
+4.29%
|
565.95
+5.18%
|
538.07
|
| Retained Earnings |
|
-101.13
+38.34%
|
-164.00
+29.67%
|
-233.19
+17.12%
|
-281.34
|
| Gains Losses Not Affecting Retained Earnings |
|
0.32
+480.00%
|
0.06
+292.86%
|
0.01
|
0.00
|
| Treasury Stock |
|
222.51
+12.66%
|
197.50
+43.76%
|
137.38
+121.85%
|
61.92
|
| Other Equity Adjustments |
|
0.32
+480.00%
|
0.06
+292.86%
|
0.01
|
—
|
| Total Equity Gross Minority Interest |
|
301.68
+31.83%
|
228.84
+17.10%
|
195.43
+0.30%
|
194.84
|
| Total Capitalization |
|
1,082.00
+6.42%
|
1,016.75
+49.68%
|
679.27
-7.37%
|
733.29
|
| Working Capital |
|
251.38
+1022.40%
|
-27.25
-134.20%
|
79.69
+680.08%
|
-13.74
|
| Invested Capital |
|
1,111.00
+2.74%
|
1,081.33
+25.36%
|
862.60
-3.71%
|
895.79
|
| Total Debt |
|
814.86
-5.17%
|
859.30
+27.44%
|
674.28
-4.92%
|
709.17
|
| Net Debt |
|
578.07
-26.07%
|
781.92
+82.60%
|
428.22
-18.78%
|
527.26
|
| Capital Lease Obligations |
|
5.54
-18.66%
|
6.81
-4.25%
|
7.11
-13.52%
|
8.22
|
| Net Tangible Assets |
|
-513.76
+37.72%
|
-824.89
-129.05%
|
-360.13
+28.87%
|
-506.32
|
| Tangible Book Value |
|
-513.76
+37.72%
|
-824.89
-129.05%
|
-360.13
+28.87%
|
-506.32
|
| Interest Payable |
|
12.02
+95.62%
|
6.15
+115.42%
|
2.85
+102.34%
|
1.41
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
329.32
+60.66%
|
204.98
-25.39%
|
274.75
+121.16%
|
124.23
|
| Cash Flow From Continuing Operating Activities |
|
329.32
+60.66%
|
204.98
-25.39%
|
274.75
+121.16%
|
124.23
|
| Net Income From Continuing Operations |
|
62.87
-9.13%
|
69.19
+43.68%
|
48.16
+292.60%
|
-25.00
|
| Depreciation Amortization Depletion |
|
226.07
+33.65%
|
169.16
+13.34%
|
149.26
+7.43%
|
138.94
|
| Depreciation |
|
4.18
+8.45%
|
3.86
+10.30%
|
3.50
+30.25%
|
2.68
|
| Amortization Cash Flow |
|
221.89
+34.23%
|
165.30
+13.41%
|
145.76
+6.98%
|
136.25
|
| Depreciation And Amortization |
|
226.07
+33.65%
|
169.16
+13.34%
|
149.26
+7.43%
|
138.94
|
| Amortization Of Intangibles |
|
221.89
+34.23%
|
165.30
+13.41%
|
145.76
+6.98%
|
136.25
|
| Other Non Cash Items |
|
5.45
-18.94%
|
6.72
-19.56%
|
8.36
-1.97%
|
8.52
|
| Stock Based Compensation |
|
41.91
+29.34%
|
32.40
+19.40%
|
27.14
+18.63%
|
22.87
|
| Deferred Tax |
|
-25.66
+4.31%
|
-26.81
-1145.42%
|
-2.15
+74.34%
|
-8.39
|
| Deferred Income Tax |
|
-25.66
+4.31%
|
-26.81
-1145.42%
|
-2.15
+74.34%
|
-8.39
|
| Operating Gains Losses |
|
15.99
+41.18%
|
11.33
-51.80%
|
23.50
|
—
|
| Change In Working Capital |
|
3.76
+106.84%
|
-54.98
-352.99%
|
21.73
+270.94%
|
-12.71
|
| Change In Receivables |
|
17.20
+489.76%
|
-4.41
-222.82%
|
3.59
+116.50%
|
-21.78
|
| Changes In Account Receivables |
|
17.20
+489.76%
|
-4.41
-222.82%
|
3.59
+116.50%
|
-21.78
|
| Change In Inventory |
|
-5.35
-138.44%
|
13.93
-1.71%
|
14.17
-70.65%
|
48.27
|
| Change In Prepaid Assets |
|
-7.97
+43.37%
|
-14.07
-1077.76%
|
1.44
+131.24%
|
-4.61
|
| Change In Payables And Accrued Expense |
|
0.07
+100.15%
|
-50.42
-2093.71%
|
2.53
+107.31%
|
-34.60
|
| Change In Accrued Expense |
|
-6.64
+83.03%
|
-39.14
-1445.93%
|
-2.53
+92.53%
|
-33.90
|
| Change In Payable |
|
6.72
+159.57%
|
-11.28
-322.84%
|
5.06
+815.84%
|
-0.71
|
| Change In Account Payable |
|
6.72
+159.57%
|
-11.28
-322.84%
|
5.06
+815.84%
|
-0.71
|
| Change In Other Working Capital |
|
-0.20
|
—
|
—
|
0.00
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
-63.53
+77.92%
|
-287.76
-306.37%
|
-70.81
+87.66%
|
-573.69
|
| Cash Flow From Continuing Investing Activities |
|
-63.53
+77.92%
|
-287.76
-306.37%
|
-70.81
+87.66%
|
-573.69
|
| Net PPE Purchase And Sale |
|
-1.74
-5.33%
|
-1.65
-258.35%
|
-0.46
+71.58%
|
-1.62
|
| Purchase Of PPE |
|
-1.74
-5.33%
|
-1.65
-258.35%
|
-0.46
+71.58%
|
-1.62
|
| Capital Expenditure |
|
-1.74
-5.33%
|
-1.65
-258.35%
|
-0.46
+71.58%
|
-1.62
|
| Net Investment Purchase And Sale |
|
-61.79
-232.77%
|
-18.57
+73.61%
|
-70.35
|
0.00
|
| Purchase Of Investment |
|
-126.97
-14.21%
|
-111.17
-20.38%
|
-92.35
|
0.00
|
| Sale Of Investment |
|
65.18
-29.62%
|
92.60
+320.92%
|
22.00
|
0.00
|
| Net Business Purchase And Sale |
|
0.00
+100.00%
|
-267.54
|
0.00
+100.00%
|
-572.07
|
| Purchase Of Business |
|
0.00
+100.00%
|
-267.54
|
0.00
+100.00%
|
-572.07
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
-110.25
-81.91%
|
-60.60
+56.77%
|
-140.18
-132.10%
|
436.72
|
| Cash Flow From Continuing Financing Activities |
|
-110.25
-81.91%
|
-60.60
+56.77%
|
-140.18
-132.10%
|
436.72
|
| Net Issuance Payments Of Debt |
|
-70.38
-1036.07%
|
7.52
+111.41%
|
-65.92
-114.89%
|
442.68
|
| Issuance Of Debt |
|
565.17
+80.47%
|
313.18
+33.14%
|
235.22
-54.56%
|
517.68
|
| Repayment Of Debt |
|
-635.56
-107.93%
|
-305.66
-1.50%
|
-301.14
-301.52%
|
-75.00
|
| Long Term Debt Issuance |
|
565.17
+80.47%
|
313.18
+33.14%
|
235.22
-54.56%
|
517.68
|
| Long Term Debt Payments |
|
-635.56
-107.93%
|
-305.66
-1.50%
|
-301.14
-301.52%
|
-75.00
|
| Net Long Term Debt Issuance |
|
-70.38
-1036.07%
|
7.52
+111.41%
|
-65.92
-114.89%
|
442.68
|
| Net Common Stock Issuance |
|
-25.10
+58.18%
|
-60.02
+19.97%
|
-75.00
-433.31%
|
-14.06
|
| Common Stock Payments |
|
-25.10
+58.18%
|
-60.02
+19.97%
|
-75.00
-433.31%
|
-14.06
|
| Repurchase Of Capital Stock |
|
-25.10
+58.18%
|
-60.02
+19.97%
|
-75.00
-433.31%
|
-14.06
|
| Proceeds From Stock Option Exercised |
|
5.64
-49.04%
|
11.07
+21.67%
|
9.10
-25.08%
|
12.15
|
| Net Other Financing Charges |
|
-20.40
-6.42%
|
-19.17
-129.28%
|
-8.36
-106.75%
|
-4.04
|
| Changes In Cash |
|
155.55
+208.48%
|
-143.38
-324.88%
|
63.76
+600.54%
|
-12.74
|
| Beginning Cash Position |
|
96.61
-59.74%
|
239.99
+36.18%
|
176.24
-6.74%
|
188.97
|
| End Cash Position |
|
252.16
+161.00%
|
96.61
-59.74%
|
239.99
+36.18%
|
176.24
|
| Free Cash Flow |
|
327.58
+61.11%
|
203.33
-25.87%
|
274.29
+123.71%
|
122.61
|
| Interest Paid Supplemental Data |
|
68.76
+10.13%
|
62.43
-14.77%
|
73.26
+39.46%
|
52.53
|
| Income Tax Paid Supplemental Data |
|
60.04
+15.26%
|
52.09
+115.20%
|
24.20
+132.74%
|
10.40
|
| Amortization Of Securities |
|
-1.07
+47.14%
|
-2.03
-64.21%
|
-1.24
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-07 View
- 42026-04-03 View
- 42026-03-20 View
- 8-K2026-03-19 View
- 42026-03-11 View
- 42026-03-05 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-12 View
- 8-K2026-01-08 View
- 8-K2025-12-30 View
- 42025-12-10 View
- 42025-12-09 View
- 42025-11-14 View
- 42025-11-14 View
- 42025-11-07 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|